Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Evogene ( (EVGN) ) has shared an announcement.
On December 30, 2025, Israel-based Evogene Ltd. announced that it has appointed Dr. Olga Nissan as its Vice President of Business Development, effective January 1, 2026, marking a key addition to its leadership team. Dr. Nissan brings more than 15 years of experience across biotechnology, pharmaceuticals, diagnostics and agri-biotechnology, with previous roles including CEO and Co-Founder of Protica Bio and positions at EcoPhage, BiomX and Teva Pharmaceutical Industries; the company’s leadership expects her expertise in AI-enabled drug discovery, strategic partnerships and company-building to support the scaling of Evogene’s ChemPass AI-driven small-molecule discovery and optimization activities and to strengthen collaborations with industry partners.
The most recent analyst rating on (EVGN) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.
Spark’s Take on EVGN Stock
According to Spark, TipRanks’ AI Analyst, EVGN is a Neutral.
Evogene’s overall stock score is primarily impacted by its weak financial performance and poor valuation metrics. While the earnings call provided some positive insights into cost management and strategic initiatives, the company’s financial instability and bearish technical indicators weigh heavily on the score.
To see Spark’s full report on EVGN stock, click here.
More about Evogene
Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. Its core technology, the ChemPass AI engine, uses generative AI to create novel, highly potent small molecules optimized across multiple parameters, aiming to improve success rates and reduce time and costs in drug and product development. Through a combination of strategic partnerships and internal product development, Evogene focuses on delivering “real-world innovation” that aligns advanced scientific capabilities with industry needs.
Average Trading Volume: 80,758
Technical Sentiment Signal: Strong Sell
Current Market Cap: $9.02M
See more data about EVGN stock on TipRanks’ Stock Analysis page.